BioHarvest Sciences (NASDAQ:BHST) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) issued its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01, FiscalAI reports. The company had revenue of $7.87 million during the quarter, compared to analyst estimates of $9.31 million. BioHarvest Sciences had a negative return on equity of 58.30% and a negative net margin of 31.21%.

BioHarvest Sciences Price Performance

BHST stock traded up $0.01 during mid-day trading on Thursday, hitting $1.75. 113,301 shares of the stock were exchanged, compared to its average volume of 35,388. The business has a fifty day moving average price of $1.65 and a 200 day moving average price of $3.11. BioHarvest Sciences has a 12 month low of $1.37 and a 12 month high of $8.30. The stock has a market capitalization of $34.43 million, a price-to-earnings ratio of -3.37 and a beta of 0.93.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Roth Capital dropped their target price on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Monday, September 14th. Finally, Maxim Group decreased their price target on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioHarvest Sciences presently has a consensus rating of “Hold” and a consensus price target of $6.50.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.